참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | tert-Butyl piperazine-1-carboxylate | HCID 143452 | — |
| 반응물 | N-(3-bromo-4-methoxyphenyl)acetamide | HCID 244158 | — |
| 시약 | Sodium t-butoxide | HCID 23676156 | — |
| 촉매 | Palladium (II) acetate | HCID 4144353 | — |
| 촉매 | 2-Dicyclohexylphosphino-2',6'-diisopropoxybiphenyl | HCID 16217985 | — |
| 용매 | Toluene | HCID 1140 | — |
| 생성물 | N-(4-methoxy-3-piperazin-1-yl-phenyl)-acetamide | HCID 82480614 | 50.91% |
반응 단계
A solution of N-(3-bromo-4-methoxyphenyl)acetamide (0.5 g, 2.05 mmol) dissolved in toluene (5 mL) was treated with tert-butyl piperazine-1-carboxylate (0.382 g, 2.05 mmol), diacetoxypalladium (0.046 g, 0.20 mmol), dicyclohexyl(2',6'-diisopropoxybiphenyl-2-yl)phosphine (0.191 g, 0.41 mmol) and sodium 2-methylpropan-2-olate (0.433 g, 4.51 mmol) in a sealed tube. The resulting mixture was degassed and stirred at 100 °C for 8 hours in a microwave. The mixture was pre-absorbed onto silica. The crude product was purified by flash silica chromatography, elution 50% ethyl acetate in Heptane. Pure fractions were evaporated to dryness to afford intermediate. The intermediate was dissolved in 4M HCl in dioxane (10mL) and stirred at RT overnight. The mixture was evaporated to give N-(4-methoxy-3-(piperazin-1-yl)phenyl)acetamide (0.260 g, 50.9 %) as a tan solid.
출처 및 근거
| 출처 데이터셋 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-d3fce1c8e3204b57a80e5c0d53c5c1f7 |
|---|
| 출처 메모 | 750 AstraZeneca ELN dataset |
|---|